Long intergenic non-coding RNA 894 (LINC00894)

Long intergenic non-coding RNA 894 (LINC00894; also known as EOLA2 divergent transcript or EOLA2-DT) is a long non-coding RNA (lncRNA) situated in an intergenic region of the human genome[1][7]. It does not encode a protein. LINC00894 is implicated in regulation of gene expression by acting as a competing endogenous RNA (ceRNA) that can bind microRNAs, such as miR-429, thereby regulating downstream targets like ZEB1[2]. LINC00894 enhances proliferation and survival of neuronal and cancer cells, modulates apoptosis (notably via ATF3 and Caspase 3 pathways), and promotes drug resistance (such as oxaliplatin resistance in hepatocellular carcinoma by binding and stabilizing Annexin A2)[1][2]. Elevated expression of LINC00894 has been observed in several disease contexts including breast cancer and hepatocellular carcinoma, where it contributes to proliferation, invasion, and chemoresistance[1][2]. Knockdown of LINC00894 increases apoptosis and reduces cell viability in neuronal and cancer cell models[1]. LINC00894 has also been shown to regulate responses to cerebral ischemia/reperfusion injury by stabilizing EIF5 and facilitating ATF4-mediated induction of neuroprotective genes[1]. LINC00894/EOLA2-DT is not a protein, enzyme, transporter, or receptor, and is not currently recognized as a direct therapeutic target in the conventional sense (such as a receptor or enzyme targeted by small molecules or antibodies)[1][2][7].

Other names

EOLA2 divergent transcriptEOLA2-DTLINC00894

Not applicable; no drugs are currently known to target this lncRNA directly